Reporting owner · CIK 0002009236

Pitofsky Jason

SEC Form 4 history for the last 180 days across 1 company, 14 transactions and 1 filing.

CTRLSVP ControllerREGENERON PHARMACEUTICALS, INC.
Open-market transaction mix0% buys0 buys · 8 sales

Period: Last 180 days

Trade dates in this period: Nov 4, 2026 – Nov 4, 2026

Transaction history, summary figures and purchase returns cover the last 180 days. Earlier activity is excluded from those sections.

Filings1Form 4 records
Buying$00 purchases
Selling$3.83M8 sales
Net value−$3.83MBuys minus sells · disclosed values

Latest insider transactions

Form 4 filings from the last 180 days.
Pitofsky Jason transactions · 20 per page
CompanyActivityDisclosed valueFiled (ET)
REGNREGENERON PHARMACEUTICALS, INC.
Controller
CTRL
Option exercise
Form 4 code M. Exercise or conversion of a derivative security exempt under Rule 16b-3.
Derivative securitySEC filing ↗
$0View disclosure →
REGNREGENERON PHARMACEUTICALS, INC.
Controller
CTRL
Option exercise
Form 4 code M. Exercise or conversion of a derivative security exempt under Rule 16b-3.
Derivative securitySEC filing ↗
$0View disclosure →
REGNREGENERON PHARMACEUTICALS, INC.
Controller
CTRL
Option exercise
Form 4 code M. Exercise or conversion of a derivative security exempt under Rule 16b-3.
Derivative securitySEC filing ↗
$0View disclosure →
REGNREGENERON PHARMACEUTICALS, INC.
Controller
CTRL
Sell
Form 4 code S. Open-market or private sale of a non-derivative or derivative security.
SEC filing ↗
−$170kView disclosure →
REGNREGENERON PHARMACEUTICALS, INC.
Controller
CTRL
Sell
Form 4 code S. Open-market or private sale of a non-derivative or derivative security.
SEC filing ↗
−$33.1kView disclosure →
REGNREGENERON PHARMACEUTICALS, INC.
Controller
CTRL
Sell
Form 4 code S. Open-market or private sale of a non-derivative or derivative security.
SEC filing ↗
−$102kView disclosure →
REGNREGENERON PHARMACEUTICALS, INC.
Controller
CTRL
Sell
Form 4 code S. Open-market or private sale of a non-derivative or derivative security.
SEC filing ↗
−$499kView disclosure →
REGNREGENERON PHARMACEUTICALS, INC.
Controller
CTRL
Sell
Form 4 code S. Open-market or private sale of a non-derivative or derivative security.
SEC filing ↗
−$1.14MView disclosure →
REGNREGENERON PHARMACEUTICALS, INC.
Controller
CTRL
Sell
Form 4 code S. Open-market or private sale of a non-derivative or derivative security.
SEC filing ↗
−$925kView disclosure →
REGNREGENERON PHARMACEUTICALS, INC.
Controller
CTRL
Sell
Form 4 code S. Open-market or private sale of a non-derivative or derivative security.
SEC filing ↗
−$541kView disclosure →
REGNREGENERON PHARMACEUTICALS, INC.
Controller
CTRL
Sell
Form 4 code S. Open-market or private sale of a non-derivative or derivative security.
SEC filing ↗
−$412kView disclosure →
REGNREGENERON PHARMACEUTICALS, INC.
Controller
CTRL
Option exercise
Form 4 code M. Exercise or conversion of a derivative security exempt under Rule 16b-3.
SEC filing ↗
$445kView disclosure →
REGNREGENERON PHARMACEUTICALS, INC.
Controller
CTRL
Option exercise
Form 4 code M. Exercise or conversion of a derivative security exempt under Rule 16b-3.
SEC filing ↗
$953kView disclosure →
REGNREGENERON PHARMACEUTICALS, INC.
Controller
CTRL
Option exercise
Form 4 code M. Exercise or conversion of a derivative security exempt under Rule 16b-3.
SEC filing ↗
$1.09MView disclosure →

Latest Form 4 facts

Quick context from source filings

Latest open-market transaction

The insider reported a sale at REGENERON PHARMACEUTICALS, INC. on Nov 4, 2026 valued at $170,186.04.

Review SEC filing
Latest buy

No open-market insider purchase is available.

Monthly open-market activity

Last 1 reported month · purchases and sales

View exact monthly values
Monthly open-market source values
MonthPurchasesSalesBuy valueSale valueNet value
Nov 202608$0$3,827,159.46−$3,827,159.46

Net value is disclosed purchases minus sales, not profit. A dash means the value is unavailable.

Ownership and transaction size

Ownership and ticket size

Average P/S size$478k
Median P/S size$456k
Direct13
Indirect1
Nov 4, 2026exercise

Associated companies

Counts cover all available history, including outside the summary period

Open-market buy performance

90-day forward return on this insider's open-market purchases

90d forward
No open-market purchases in the last 180 days

A 90-day purchase return requires an open-market buy. None is recorded in the last 180 days. Purchases filed earlier are outside the visible history and are not included.

Disclosed ownership

How reported shareholdings evolved

Non-derivative shares held after reported transactions—not stock prices or a complete portfolio.

10 observations · Nov 4, 2026 – Nov 4, 2026. Window ends at the latest available report, not today.

Selected observation · Nov 4, 20264,272 shares reported
Inspect transaction
View exact observations and source transactions
Transaction dateShares held afterFiledSource
Nov 4, 20265,772Nov 6, 2026View transaction
Nov 4, 20267,250Nov 6, 2026View transaction
Nov 4, 20268,155Nov 6, 2026View transaction
Nov 4, 20267,716Nov 6, 2026View transaction
Nov 4, 20267,141Nov 6, 2026View transaction
Nov 4, 20266,159Nov 6, 2026View transaction
Nov 4, 20264,944Nov 6, 2026View transaction
Nov 4, 20264,415Nov 6, 2026View transaction
Nov 4, 20264,307Nov 6, 2026View transaction
Nov 4, 20264,272Nov 6, 2026View transaction

Securities and direct/indirect ownership contexts are kept separate and never summed. Joint filings may associate the same disclosed row with multiple owners. Unknown values are omitted, not treated as zero. Lines connect observations for readability; they do not establish holdings between filings, cost basis, or current ownership. Amendments and stock splits require reviewing the source.

Pitofsky Jason Insider Activity FAQ

SEC Form 4 context

Who is Pitofsky Jason?

Pitofsky Jason is a reporting owner in SEC Form 4 filings with reporting owner CIK 0002009236.

Which companies has Pitofsky Jason reported transactions for?

REGENERON PHARMACEUTICALS, INC.

When was Pitofsky Jason's latest insider buy?

No open-market insider purchase is recorded in the last 180 days. Earlier filings are outside the visible history.

When was Pitofsky Jason's latest insider sale?

The insider reported a sale at REGENERON PHARMACEUTICALS, INC. on Nov 4, 2026 valued at $170,186.04.

Where can I see the original SEC filings?

Each transaction row links directly to the source SEC filing so the reported Form 4 details can be reviewed.

Are performance metrics included?

The profile shows average and median 90-day stock returns after open-market purchases when price coverage is available. These are unadjusted stock returns, not realized trading gains. Win rates, benchmark-adjusted returns and conviction scores are not calculated.